Why ArriVent BioPharma, Inc.’s (AVBP) Stock Is Down 6.04%
As of Monday, July 20, ArriVent BioPharma, Inc.’s AVBP share price has dipped by 6.04%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Commentary & Analysis
Why ArriVent BioPharma, Inc.’s (AVBP) Stock Is Up 5.14%
As of Thursday, June 25, ArriVent BioPharma, Inc.’s AVBP share price has surged by 5.14%, which has investors questioning if this is right time to sell.Michael Rose
Why ArriVent BioPharma, Inc.’s (AVBP) Stock Is Up 5.03%
As of Tuesday, June 23, ArriVent BioPharma, Inc.’s AVBP share price has surged by 5.03%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why ArriVent BioPharma, Inc.’s (AVBP) Stock Is Up 5.32%
As of Monday, June 22, ArriVent BioPharma, Inc.’s AVBP share price has surged by 5.32%, which has investors questioning if this is right time to sell.Michael Rose
Why ArriVent BioPharma, Inc.’s (AVBP) Stock Is Down 6.62%
As of Friday, June 05, ArriVent BioPharma, Inc.’s AVBP share price has dipped by 6.62%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | AVBP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,388.9 | $252.6 | 49% |
|
| Shares Out (Mil) | 45.1 | 52.3 | 45% |
|
| Institutional Ownership | 97.3% | 92.1% | 73% |
|
| Float (Mil) | 29.8 | 40.2 | 36% |
|
| Beta | 1.52 | 0.95 | 83% |
|
| Avg Daily Volume (000s) | 569 | 455 | 61% |
|
| Price Change (52-week) |
52.2% | 52.9% | 81% |
|
| Growth | AVBP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (9.9%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 11 | 9 | |
| Current EPS | ($0.984) | ($4.088) | ($3.479) | |
| Month Ago EPS | ($0.985) | ($4.024) | ($3.499) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 2 | 0 | 1 | |
| Three Months Ago EPS | ($0.898) | ($3.761) | ($3.185) | |
| Year/Year Chg | 2.4% | (5.5%) | (75.2%) | |
| Financials | AVBP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($145) | ($43) | 8% |
|
| EPS (TTM) | ($3.521) | ($1.600) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($135) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $12 | $5 | 59% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 13% |
|
| Enterprise Value (Q1) (Mil) | $1,023 | $180 | 41% |
|
| Valuation | AVBP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.17 | 2.56 | 74% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | AVBP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (51.4%) | (49.8%) | 11% |
|
| ROE | (55.2%) | (55.5%) | 14% |
|
| Liabilities to Assets | 7.2% | 30.3% | 4% |
|
| F-Score | 1 | 3 | 1% |
|
ArriVent BioPharma, Inc. did not pass any screens on 7/31/2026.
